Jimmy Carter, ex-U.S President who turned 100, survived brain cancer for 9 years; here's how he did it
Former US President Jimmy Carter, who was diagnosed with melanoma that spread to his brain in 2015, has survived for nine ...
Merus Announces First Patient Dosed in LiGeR-HN1, a Phase 3 Trial Evaluating Petosemtamab in Combination with Pembrolizumab in 1L r/m HNSCC
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a ...
2minutemedicine.com3d
Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer
The 5-year OS rate for pembrolizumab vs placebo was 86.1% vs 81.7% with HR 0.51 (significant). 2. Immune-mediated adverse ...
Medscape3d
FDA Panel Votes for Limits on Gastric, Esophageal Cancer Immunotherapy
After hours of company pushback, FDA's Oncologic Drugs Advisory Committee voted that the benefit of immunotherapy in low or ...
Cancer spread to Jimmy Carter's brain 9 years ago. Here's how he's lived so long.
A new approach to cancer treatment became available shortly before Jimmy Carter needed it. Now it's a pillar of care.
MedPage Today6d
No Benefit for PD-1 Inhibitors in Certain Gastroesophageal Cancers, FDA Panel Says
By way of two resoundingly consistent votes, members of an FDA advisory committee agreed that PD-1 inhibitors do not have a favorable risk/benefit profile for gastroesophageal cancers with low PD-L1 ...
Targeted Oncology6d
Olomorasib Combo Elicits Favorable Efficacy in NSCLC
Olomorasib with pembrolizumab in the first-line showed a 77% overall response rate in patients with KRAS G12C–mutated ...
The American Journal of Managed Care6d
Combined Chemotherapy and Immunotherapy Improves Outcomes in PAH
An adult patient with pulmonary arterial hypertension (PAH) and metastatic lung adenocarcinoma showed significant clinical ...